金龙胶囊联合介入治疗对原发性肝癌患者免疫功能调节作用的观察

Regulation of immune functions by combined Jinlong capsule and interventional therapy in patients with primary liver cancer

    摘要
  • 摘要:
      目的  观察金龙胶囊联合介入治疗对原发性肝癌患者免疫功能的调节作用。
      方法  随机选择经临床确诊为中晚期原发性肝癌的住院患者60例，随机分为观察组和对照组，观察组患者在介入治疗后第3天开始口服金龙胶囊，3次/日，4粒/次，30 d为1个疗程。对照组患者仅进行介入治疗。治疗过程中两组均不使用其他免疫调节剂。两组患者均于介入治疗前3~5 d及介入治疗后1个月采集外周血标本检测细胞免疫功能指标。
      结果  观察组患者介入治疗后外周血CD3、CD4、NK细胞、CD4/CD8比值、SIL-2R和TSGF数量（均值）与治疗前均无显著变化。对照组患者介入治疗后外周血CD3、CD4、NK细胞、CD4/CD8比值、SIL-2R和TSGF数量（均值）较治疗前均显著降低（P< 0.05）。
      结论  金龙胶囊有助于原发性肝癌患者介入治疗后细胞免疫功能的恢复。

     

    Abstract:
      Objective  To determine the effects of Jinlong capsule combined with interventional therapy on the immune functions of primary hepatocellular carcinoma patients.
      Methods  Sixty randomly selected cases of clinically diagnosed primary hepatocellular carcinoma were divided into the observation group and the control group. Three days after operation, the observation group was given four Jinlong capsules three times a day for 30 days (one treatment). Meanwhile, the control group received interventional therapy after the operation. One to four days following one treatment, peripheral blood specimens were collected from the two groups to determine the cellular immune function indices.
      Results  The cell numbers (mean) of the peripheral blood components CD3, CD4, NK, SIL-2R, TSGF, and SIL-2R and the CD4/CD8 ratio in the observation group showed no significant difference before and after treatment. In the control group, these indices were significantly different before and after treatment.
      Conclusion  The Jinlong capsule facilitates the cellular immunity recovery of patients with primary hepatocellular carcinoma after interventional therapy.

     

    • HTML全文
    • 参考文献(18)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回